Lisa G. Horvath

University of Sydney — Australia

Medicine · Health Sciences

63h-index13.6kcitations464works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(229), Cancer, Lipids, and Metabolism(104), Radiopharmaceutical Chemistry and Applications(73), Cancer Immunotherapy and Biomarkers(47), Epigenetics and DNA Methylation(45)

Publications462 total

Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges
European Urology Focus·2025Open Access
Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells
EBioMedicine·2025Open Access
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology·2025· 3 cited
Supplementary Table S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025· 1 citedOpen Access
Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure 9 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Supplementary Figure 1 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Supplementary Figure 6 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Supplementary Figure 11 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Table S4 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Table S2 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Supplementary Figure 4 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Supplementary Figure 13 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Data from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Table S3 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
Table S5 from Federated Deep Learning Enables Cancer Subtyping by Proteomics
2025Open Access
page 1 of 24Next →

Frequent Co-authors

James G. Kench(14), Phillip D. Stricker(13), Robert L. Sutherland(13), Susan M. Henshall(11), Anthony M. Joshua(8), Ian D. Davis(7), Martin R. Stockler(7), Wayne D. Tilley(7), Mark Frydenberg(6), Gavin Marx(6), Shahneen Sandhu(6), Gail P. Risbridger(6), John J. Grygiel(6), Susan J. Clark(6), Kim N.(5), Simon Chowdhury(5), David Pook(5), Christopher J. Sweeney(5), Jyotsna Batra(5), David E. Neal(5)